We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:

Search Results

Showing 1-20 of 2,346 results
  1. Clinical Pharmacokinetics and Pharmacodynamics of Esaxerenone, a Novel Mineralocorticoid Receptor Antagonist: A Review

    Esaxerenone is a selective, nonsteroidal, high-affinity mineralocorticoid receptor antagonist recently approved in Japan for the treatment of...

    Slobodan M. Janković, Snežana V. Janković in European Journal of Drug Metabolism and Pharmacokinetics
    Article 21 February 2022
  2. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Ocedurenone (KBP-5074) in Individuals with Moderate Hepatic Impairment

    Background and Objectives

    Ocedurenone (KBP-5074) is a novel nonsteroidal mineralocorticoid receptor antagonist that has demonstrated safety and...

    James McCabe, Jay Zhang, ... Vincent Benn in European Journal of Drug Metabolism and Pharmacokinetics
    Article Open access 08 February 2024
  3. Effects of Glucocorticoid Hormones on Pain Sensitivity: Involvement of Glucocorticoid and Mineralocorticoid Receptors

    Glucocorticoid hormones are widely used in the clinic as analgesic and anti-inflammatory drugs for various types of pain. The actions of...

    N. I. Yarushkina, L. P. Filaretova in Neuroscience and Behavioral Physiology
    Article 01 May 2023
  4. Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage

    Proinflammatory cytokines target vascular endothelial cells during COVID-19 infections. In particular, the endothelial glycocalyx (eGC), a...

    Benedikt Fels, Sovon Acharya, ... Kristina Kusche-Vihrog in PflĂĽgers Archiv - European Journal of Physiology
    Article Open access 22 July 2022
  5. Apparent mineralocorticoid excess: comprehensive overview of molecular genetics

    Apparent mineralocorticoid excess is an autosomal recessive form of monogenic disease characterized by juvenile resistant low-renin hypertension,...

    Yi-ting Lu, Di Zhang, ... Fan Peng in Journal of Translational Medicine
    Article Open access 03 November 2022
  6. Molecular Pharmacology of the Youngest Member of the Nuclear Receptor Family: The Mineralocorticoid Receptor

    The mineralocorticoid receptor (MR) was the last member of the nuclear receptor superfamily to evolve. It is responsible for the maintenance of the...
    Mario D. Galigniana in Nuclear Receptors
    Chapter 2021
  7. Role of glucocorticoid receptor mutations in hypertension and adrenal gland hyperplasia

    Hypertension is one of the leading causes of premature death in humans and exhibits a complex aetiology including environmental and genetic factors....

    Sophia Verouti, Edith Hummler, Paul-Emmanuel Vanderriele in PflĂĽgers Archiv - European Journal of Physiology
    Article Open access 22 June 2022
  8. Selective deletion of endothelial mineralocorticoid receptor protects from vascular dysfunction in sodium-restricted female mice

    Background

    Recent evidence by our laboratory demonstrates that women and female mice endogenously express higher endothelial mineralocorticoid...

    Jessica L. Faulkner, Emily Lluch, ... Eric J. Belin de Chantemèle in Biology of Sex Differences
    Article Open access 23 November 2020
  9. Histamine H2-receptor antagonism improves conduit artery endothelial function and reduces plasma aldosterone level without lowering arterial blood pressure in angiotensin II–hypertensive mice

    Aldosterone through the mineralocorticoid receptor MR has detrimental effects on cardiovascular disease. It reduces the bioavailability of nitric...

    Kasper B. Assersen, Boye L. Jensen, ... Pernille B. L. Hansen in PflĂĽgers Archiv - European Journal of Physiology
    Article Open access 27 January 2024
  10. Cardiovascular risks of androgen receptor targeted agents in prostate cancer: a systematic review and meta-analysis

    Introduction

    Androgen receptor targeted agents (ARTA) have increasingly been incorporated into treatment regimens for various stages of prostate...

    Chloe Shu Hui Ong, Yu ** Terence Law, ... Edmund Chiong in Prostate Cancer and Prostatic Diseases
    Article 24 January 2024
  11. Repurposing of IL 33/ST2 Modulating Drugs as a Cardioprotective Agent: A Promising Approach

    Drug repurposing has emerged as an enigmatic clinical approach in disorders affecting the cardiovascular system. The concept of drug repurposing has...

    Punniyakoti Veeraveedu Thanikachalam, Srinivasan Ramamurthy, ... Bharathi Radhakrishnan in Journal of Pharmaceutical Innovation
    Article 20 February 2024
  12. Neurosteroid Receptor Modulators for Treating Traumatic Brain Injury

    Traumatic brain injury (TBI) triggers wide-ranging pathology that impacts multiple biochemical and physiological systems, both inside and outside the...

    Todd A. Verdoorn, Tom J. Parry, ... Jonathan Lifshitz in Neurotherapeutics
    Article Open access 31 August 2023
  13. A tumour suppressive relationship between mineralocorticoid and retinoic acid receptors activates a transcriptional program consistent with a reverse Warburg effect in breast cancer

    Background

    The role of nuclear receptors in both the aetiology and treatment of breast cancer is exemplified by the use of the oestrogen receptor (ER)...

    Tram B. Doan, Vanessa Cheung, ... J. Dinny Graham in Breast Cancer Research
    Article Open access 04 November 2020
  14. Protein Condensation in the Nuclear Receptor Family; Implications for Transcriptional Output

    The nuclear receptorNuclear receptors superfamily is a group of transcriptional regulators that orchestrate multiple vital processes such as...
    Monique D. Appelman, Elle E. Hollaar, ... Saskia W. C. van Mil in Nuclear Receptors in Human Health and Disease
    Chapter 2022
  15. Glucocorticoid Receptor Down-Regulation Affects Neural Stem Cell Proliferation and Hippocampal Neurogenesis

    Dysregulation of the hypothalamic–pituitary–adrenal axis and abnormalities in the glucocorticoid receptor (GR) have been linked to major depressive...

    Seoyeong Kim, Seonguk Yang, ... Jaewon Lee in Molecular Neurobiology
    Article 18 November 2023
  16. Stress-induced Neuroinflammation of the Spinal Cord is Restrained by Cort113176 (Dazucorilant), A Specific Glucocorticoid Receptor Modulator

    Glucocorticoids exert antiinflammatory, antiproliferative and immunosupressive effects. Paradoxically they may also enhance inflammation particularly...

    Maria Meyer, Onno Meijer, ... Alejandro F. De Nicola in Molecular Neurobiology
    Article 11 August 2023
  17. A Genomic Study of the Japanese Population Focusing on the Glucocorticoid Receptor Interactome Highlights Distinct Genetic Characteristics Associated with Stress Response

    All living organisms have been programmed to maintain a complex inner equilibrium called homeostasis, despite numerous adversities during their...
    Thanasis Mitsis, Louis Papageorgiou, ... Dimitrios Vlachakis in GeNeDis 2022
    Conference paper 2023
  18. A potent new-scaffold androgen receptor antagonist discovered on the basis of a MIEC-SVM model

    Prostate cancer (PCa) is the second most prevalent malignancy among men worldwide. The aberrant activation of androgen receptor (AR) signaling has...

    **n-yue Wang, **n Chai, ... Dan Li in Acta Pharmacologica Sinica
    Article 15 May 2024
  19. Corticosteroid Receptors in Cardiac Health and Disease

    Nuclear receptors play a central role in both energy metabolism and cardiomyocyte death and survival in the heart. Recent evidence suggests they may...
    Jessica R. Ivy, Gillian A. Gray, ... Karen E. Chapman in Nuclear Receptors in Human Health and Disease
    Chapter 2022
  20. Sacubitril/valsartan compared to equivalent/sub-equivalent dose angiotensin receptor blocker or angiotensin-converting enzyme inhibitor in heart failure with reduced ejection fraction: a meta-analysis of randomized trials

    Purpose

    The objective of this meta-analysis is to determine how sacubitril/valsartan (SV) compares to equivalent and sub-equivalent angiotensin...

    Joseph P. Rindone, Chadwick K. Mellen in European Journal of Clinical Pharmacology
    Article 10 April 2024
Did you find what you were looking for? Share feedback.